Лекарственные формы левотироксина натрия. Есть ли место новому в лечении гипотиреоза?

Левотироксин натрия широко применяется во всем мире для лечения заболеваний, сопровождающихся сниженной функцией щитовидной железы. Несмотря на хорошо известные особенности фармакокинетики и фармакодинамики левотироксина натрия, не всем пациентам, принимающим его в таблетированной форме, удается достичь индивидуальных целей лечения. Среди основных причин неэффективности терапии — неудобный режим приема препарата с необходимостью выдерживать временные интервалы перед едой и приемом других лекарственных средств, а также целый ряд желудочно-кишечных заболеваний, влияющих на биодоступность левотироксина натрия. Данное обстоятельство способствовало появлению исследований, направленных на поиск новых лекарственных форм левотироксина, обладающих большими преимуществами с точки зрения достижения клинического эффекта в сравнении с таблетированной формой. В настоящем обзоре приведены последние данные об использовании новых лекарственных форм левотироксина. Необходимо дальнейшее проведение крупных клинических испытаний для более обоснованного и широкого использования новых лекарственных форм левотироксина в клинической практике.

1. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American thyroid association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670-1751. doi: https://doi.org/10.1089/thy.2014.0028

2. Eligar V, Taylor PN, Okosieme OE, et al. Thyroxine replacement: a clinical endocrinologist’s viewpoint. Ann Clin Biochem. 2016;53(4):421-433. doi: https://doi.org/10.1177/0004563216642255

3. Virili C, Trimboli P, Centanni M. Novel thyroxine formulations: a further step toward precision medicine. Endocrine. 2019;66(1):87-94. doi: https://doi.org/10.1007/s12020-019-02049-x

4. Castellana M, Castellana C, Giovanella L, Trimboli P. Prevalence of gastrointestinal disorders having an impact on tablet levothyroxine absorption: should this formulation still be considered as the first-line therapy? Endocrine. 2020;67(2):281-290. doi: https://doi.org/10.1007/s12020-019-02185-4

5. Моргунова Т.Б., Фадеев В.В. Заместительная терапия гипотиреоза препаратами тиреоидных гормонов — один гормон или два? // Проблемы Эндокринологии. — 2005. — Т. 51. — №1. — С. 53-56. doi: https://doi.org/10.14341/probl200551153-56

6. Bertoncini CW, Palacios MJC, Fritz MC, et al. Levothyroxine bioequivalence study and its narrow therapeutic index: comparative bioavailability results between two formulations available in Latin America. Adv Ther. 2023;40(4):1644-1654. doi: https://doi.org/10.1007/s12325-022-02352-6

7. Charles BY, Harington R, Barger G. The constitution and synthesis of thyroxine. Nature. 1927;120(3013):170. doi: https://doi.org/10.1038/120170a0

8. Hennessey JV. The emergence of levothyroxine as a treatment for hypothyroidism. Endocrine. 2017;55(1):6-18. doi: https://doi.org/10.1007/s12020-016-1199-8

9. Tanguay M, Girard J, Scarsi C, et al. Pharmacokinetics and Comparative Bioavailability of a Levothyroxine Sodium Oral Solution and Soft Capsule. Clin Pharmacol Drug Dev. 2019;8(4):521-528. doi: https://doi.org/10.1002/cpdd.608

10. Virili C, Antonelli A, Santaguida MG, et al. Gastrointestinal malabsorption of thyroxine. Endocr Rev. 2018;40(1):118-136. doi: https://doi.org/10.1210/er.2018-00168

11. Mateo RCI, Hennessey JV. Thyroxine and treatment of hypothyroidism: seven decades of experience. Endocrine. 2019;66(1):10-17. doi: https://doi.org/10.1007/s12020-019-02006-8

12. Soiza RL, Donaldson AIC, Myint PK. Vaccine against arteriosclerosis: an update. Ther Adv Vaccines. 2018;9(6):259-261. doi: https://doi.org/10.1177/https

13. Hays MT. Thyroid hormone and the gut. Endocr Res. 1988;14(2-3):203-224. doi: https://doi.org/10.3109/07435808809032986

14. Sachmechi I, Reich DM, Aninyei M, et al. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr Pract. 2007;13(4):345-349. doi: https://doi.org/10.4158/EP.13.4.345

15. Movaffagh J, Hadizadeh F, Khodaverdi E, et al. Preparation and in vitro evaluation of injectable formulations of levothyroxine sodium using in situ forming hydrogel temperature-responsive systems based on PLA-PEG-PLA and PLGA-PEG-PLGA triblock copolymers. Iran J Basic Med Sci. 2022;25(3):341-351. doi: https://doi.org/10.22038/ijbms.2022.62576.13842

16. Santini F, Pinchera A, Marsili A, et al. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J Clin Endocrinol Metab. 2005;90(1):124-127. doi: https://doi.org/10.1210/jc.2004-1306

17. Cappelli C, Castello R, Marini F, et al. Adherence to levothyroxine treatment among patients with hypothyroidism: A northeastern Italian survey. Front Endocrinol (Lausanne). 2018;(9):1-5. doi: https://doi.org/10.3389/fendo.2018.00699

18. Hays MT. Localization of human thyroxine absorption. Thyroid. 1991;1(3):241-248. doi: https://doi.org/10.1089/thy.1991.1.241

19. McLeod JG. Clinical and experimental neurology. Med J Aust. 1984;140(7):437-437. doi: https://doi.org/10.5694/j.1326-5377.1984.tb108124.x

20. Ruchała M, Bossowski A, Brzózka MM, et al. Liquid levothyroxine improves thyroid control in patients with different hypothyroidism aetiology and variable adherence — case series and review. Endokrynol Pol. 2022;73(5):893-902. doi: https://doi.org/10.5603/EP.a2022.0078

21. Centanni M, Gargano L, Canettieri G, et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med. 2006;354(17):1787-1795. doi: https://doi.org/10.1056/NEJMoa043903

22. Jojima T, Shinzawa T, Ohira E, et al. Switching from the tablet to the powder formulation of levothyroxine corrects severe hypothyroidism in a patient with lactose intolerance. Endocr J. 2022;69(8):941-945. doi: https://doi.org/10.1507/endocrj.EJ21-0656

23. Cassio A, Monti S, Rizzello A, et al. Comparison between liquid and tablet formulations of levothyroxine in the initial treatment of congenital hypothyroidism. J Pediatr. 2013;162(6):1264-1269.e2. doi: https://doi.org/10.1016/j.jpeds.2012.11.070

24. Stagi S, Municchi G, Ferrari M, Wasniewska MG. An overview on different l-thyroxine (l-t4) formulations and factors potentially influencing the treatment of congenital hypothyroidism during the first 3 years of life. Front Endocrinol (Lausanne). 2022;(13):1-19. doi: https://doi.org/10.3389/fendo.2022.859487

25. Yue C, Scarsi C, Ducharme M. Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. Arzneimittelforschung. 2012;62(12):631-636. doi: https://doi.org/10.1055/s-0032-1329951

26. Cappelli C, Pirola I, Daffini L, et al. A double-blind placebocontrolled trial of liquid thyroxine ingested at breakfast: Results of the TICO study. Thyroid. 2016;26(2):197-202. doi: https://doi.org/10.1089/thy.2015.0422

27. Pirola I, Gandossi E, Brancato D, et al. TSH evaluation in hypothyroid patients assuming liquid levothyroxine at breakfast or 30 min before breakfast. J Endocrinol Invest. 2018;41(11):1301-1306. doi: https://doi.org/10.1007/s40618-018-0867-3

28. Ducharme M, Scarsi C, Bettazzi E, Mautone G, Lewis Y, Celi FS. A Novel Levothyroxine Solution Results in Similar Bioavailability Whether Taken 30 or Just 15 Minutes before a High-Fat High-Calorie Meal. Thyroid. 2022;32(8):897-904. doi: https://doi.org/10.1089/thy.2021.0604

29. Vita R, Saraceno G, Trimarchi F, Benvenga S. Switching levothyroxine from the tablet to the oral solution formulation corrects the impaired absorption of levothyroxine induced by protonpump inhibitors. J Clin Endocrinol Metab. 2014;99(12):4481-4486. doi: https://doi.org/10.1210/jc.2014-2684

30. Benvenga S, Di Bari F, Vita R. Undertreated hypothyroidism due to calcium or iron supplementation corrected by oral liquid levothyroxine. Endocrine. 2017;56(1):138-145. doi: https://doi.org/10.1007/s12020-017-1244-2

31. Vita R, Di Bari F, Benvenga S. Oral liquid levothyroxine solves the problem of tablet levothyroxine malabsorption due to concomitant intake of multiple drugs. Expert Opin Drug Deliv. 2017;14(4):467-472. doi: https://doi.org/10.1080/17425247.2017.1290604

32. Tortora A, La Sala D, Vitale M. Switch from tablet levothyroxine to oral solution resolved reduced absorption by intestinal parasitosis. Endocrinol Diabetes Metab Case Reports. 2019;2019(12):631-636. doi: https://doi.org/10.1530/EDM-19-0026

33. Ribichini D, Fiorini G, Repaci A, et al. Tablet and oral liquid L-thyroxine formulation in the treatment of naïve hypothyroid patients with Helicobacter pylori infection. Endocrine. 2017;57(3):394-401. doi: https://doi.org/10.1007/s12020-016-1167-3

34. Fallahi P, Ferrari SM, Ruffilli I, Antonelli A. Reversible normalisation of serum TSH levels in patients with autoimmune atrophic gastritis who received L-T4 in tablet form after switching to an oral liquid formulation: A case series. BMC Gastroenterol. 2016;16(1):1-5. doi: https://doi.org/10.1186/s12876-016-0439-y

35. Fallahi P, Ferrari SM, Marchi S, et al. Patients with lactose intolerance absorb liquid levothyroxine better than tablet levothyroxine. Endocrine. 2017;57(1):175-178. doi: https://doi.org/10.1007/s12020-016-1090-7

36. Benvenga S, Capodicasa G, Perelli S, et al. Increased requirement of replacement doses of levothyroxine caused by liver cirrhosis. Front Endocrinol (Lausanne). 2018;(9):1-5. doi: https://doi.org/10.3389/fendo.2018.00150

37. Hommel C, Delgrange E. Resistance to levothyroxine in a bariatric surgery patient: an indication for liquid formulation? Acta Clin Belgica Int J Clin Lab Med. 2017;72(1):72-75. doi: https://doi.org/10.1080/17843286.2016.1196861

38. Bornikowska K, Gietka-Czernel M, Raczkiewicz D, et al. Improvements in quality of life and thyroid parameters in hypothyroid patients on ethanol-free formula of liquid levothyroxine therapy in comparison to tablet LT4 form: An observational study. J Clin Med. 2021;10(22):5233. doi: https://doi.org/10.3390/jcm10225233

39. Henderson BB. Levothyroxine sodium oral solution normalizes thyroid function in a patient with hashimoto’s disease, gastritis, diabetic gastroparesis, and small intestinal bacterial overgrowth (Sibo). Int Med Case Rep J. 2021;14(22):627-632. doi: https://doi.org/10.2147/IMCRJ.S326481

40. Virili C, Giovanella L, Fallahi P, et al. Levothyroxine therapy: Changes of TSH levels by switching patients from tablet to liquid formulation. A systematic review and meta-analysis. Front Endocrinol (Lausanne). 2018;(9):1-6. doi: https://doi.org/10.3389/fendo.2018.00010

41. Laurent I, Tang S, Astère M, et al. Liquid L-thyroxine versus tablet L-thyroxine in patients on L- thyroxine replacement or suppressive therapy: a meta-analysis. Endocrine. 2018;61(1):28-35. doi: https://doi.org/10.1007/s12020-018-1574-8

42. Ferrara R, Ientile V, Arcoraci V, et al. Treatment pattern and frequency of serum TSH measurement in users of different levothyroxine formulations: a population-based study during the years 2009–2015. Endocrine. 2017;58(1):143-152. doi: https://doi.org/10.1007/s12020-017-1242-4

43. Cappelli C, Negro R, Pirola I, et al. Levothyroxine liquid solution versus tablet form for replacement treatment in pregnant women. Gynecol Endocrinol. 2016;32(4):290-292. doi: https://doi.org/10.3109/09513590.2015.1113518

44. Guglielmi R, Grimaldi F, Negro R, et al. Shift from levothyroxine tablets to liquid formulation at breakfast improves quality of life of hypothyroid patients. Endocrine, Metab Immune Disord - Drug Targets. 2018;18(3):235-240. doi: https://doi.org/10.2174/1871530318666180125155348

45. Cappelli C, Pirola I, Gandossi E, et al. Thyroid Hormone Profile in Patients Ingesting Soft Gel Capsule or Liquid Levothyroxine Formulations with Breakfast. Int J Endocrinol. 2016;2016:1-5. doi: https://doi.org/10.1155/2016/9043450

46. Peirce C, Ippolito S, Lanas A, et al. Treatment of refractory and severe hypothyroidism with sublingual levothyroxine in liquid formulation. Endocrine. 2018;60(1):193-196. doi: https://doi.org/10.1007/s12020-017-1367-5

47. Giusti M, Mortara L, Machello N, et al. Utility of a liquid formulation of levo-thyroxine in differentiated thyroid cancer patients. Drug Res (Stuttg). 2014;65(6):332-336. doi: https://doi.org/10.1055/s-0034-1384535

48. Kaur N, Suryanarayanan R. Levothyroxine sodium pentahydrate tablets — formulation considerations. J Pharm Sci. 2021;110(12):3743-3756. doi: https://doi.org/10.1016/j.xphs.2021.08.006

49. Pabla D, Akhlaghi F, Zia H. A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry. Eur J Pharm Biopharm. 2009;72(1):105-110. doi: https://doi.org/10.1016/j.ejpb.2008.10.008

50. Trimboli P, Scappaticcio L, De Bellis A, et al. Different formulations of levothyroxine for treating hypothyroidism: A real-life study. Int J Endocrinol. 2020;2020:1-5. doi: https://doi.org/10.1155/2020/4524759

51. Vita R, Saraceno G, Trimarchi F, Benvenga S. A novel formulation of l-thyroxine (l-T4) reduces the problem of l-T4 malabsorption by coffee observed with traditional tablet formulations. Endocrine. 2013;43(1):154-160. doi: https://doi.org/10.1007/s12020-012-9772-2

52. Santaguida MG, Virili C, Duca SC Del, et al. Thyroxine softgel capsule in patients with gastric-related T4 malabsorption. Endocrine. 2015;49(1):51-57. doi: https://doi.org/10.1007/s12020-014-0476-7

53. Kim PJ, Sachmechi I. Levothyroxine malabsorption induced by diabetic gastroparesis exacerbated during pregnancies: Effect of intramuscular levothyroxine injections and levothyroxine soft gel capsules. AACE Clin Case Reports. 2015;1(1):e73-e78. doi: https://doi.org/10.4158/EP14051.CR

54. Reardon DP, Yoo PS. Levothyroxine tablet malabsorption associated with gastroparesis corrected with gelatin capsule formulation. Case Rep Endocrinol. 2016;2016(1):1-3. doi: https://doi.org/10.1155/2016/1316724

55. Di Donna V, Paragliola RM, de Waure C, et al. Is levothyroxine requirement the same for tablet and soft gel formulations? Endocrine. 2018;59(2):458-460. doi: https://doi.org/10.1007/s12020-017-1311-8

56. Benvenga S, Capodicasa G, Perelli S. l-Thyroxine in an oral liquid or softgel formulation ensures more normal serum levels of free T4 in patients with central hypothyroidism. Front Endocrinol (Lausanne). 2017;8(1):e73-e78. doi: https://doi.org/10.3389/fendo.2017.00321

57. Ernst FR, Sandulli W, Elmor R, et al. Retrospective study of patients switched from tablet formulations to a gel cap formulation of levothyroxine: Results of the CONTROL switch study. Drugs RD. 2017;17(1):103-115. doi: https://doi.org/10.1007/s40268-016-0150-z

58. Kashanian S, Rostami E. PEG-stearate coated solid lipid nanoparticles as levothyroxine carriers for oral administration. J Nanoparticle Res. 2014;16(3):2293. doi: https://doi.org/10.1007/s11051-014-2293-6

59. Parhi R, Suresh P. Production of solid lipid nanoparticles-drug loading and release mechanism. J Chem Pharmacuetical Res. 2010;2(1):211-227.

60. Üner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspective. Int J Nanomedicine. 2007;2(3):289-300.

61. Cavalli R, Gasco MR, Chetoni P, et al. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm. 2002;238(1-2):241-245. doi: https://doi.org/10.1016/S0378-5173(02)00080-7

62. FDA [Internet]. Levothyroxine sodium for injection; 2011 [cited 24.07.2023]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202231s000lbl.pdf

63. Nakano Y, Hashimoto K, Ohkiba N, et al. A case of refractory hypothyroidism due to poor compliance treated with the weekly intravenous and oral levothyroxine administration. Case Rep Endocrinol. 2019;2019:1-6. doi: https://doi.org/10.1155/2019/5986014

64. Peynirci H, Taskiran B, Erturk E, et al. Is parenteral levothyroxine therapy safe in intractable hypothyroidism? J Natl Med Assoc. 2018;110(3):245-249. doi: https://doi.org/10.1016/j.jnma.2017.05.007

65. Garayalde Gamboa MDLÁ, Saban M, Curriá MI. Treatment with intramuscular levothyroxine in refractory hypothyroidism. Eur Thyroid J. 2019;8(6):319-323. doi: https://doi.org/10.1159/000503324

66. Kashanian S, Rostami E, Harding FJ, et al. Controlled delivery of levothyroxine using porous silicon as a drug nanocontainer. Aust J Chem. 2016;69(2):204-211. doi: https://doi.org/10.1071/CH15315

67. Kamali H, Khodaverdi E, Hadizadeh F, et al. An in-situ forming implant formulation of naltrexone with minimum initial burst release using mixture of PLGA copolymers and ethyl heptanoate as an additive: In-vitro, ex-vivo, and in-vivo release evaluation. J Drug Deliv Sci Technol. 2018;47:95-105. doi: https://doi.org/10.1016/j.jddst.2018.06.027

68. Mashayekhi R, Mobedi H, Najafi J, Enayati M. In-vitro/In-vivo comparison of leuprolide acetate release from an in-situ forming plga system. DARU J Pharm Sci. 2013;21(1):57. doi: https://doi.org/10.1186/2008-2231-21-57

69. Padula C, Nicoli S, Santi P. Innovative formulations for the delivery of levothyroxine to the skin. Int J Pharm. 2009;372(1-2):12-16. doi: https://doi.org/10.1016/j.ijpharm.2008.12.028

70. Azarbayjani AF, Venugopal JR, Ramakrishna S, et al. Smart polymeric nanofibers for topical delivery of levothyroxine. J Pharm Pharm Sci. 2010;13(3):400-410. doi: https://doi.org/10.18433/j3ts3g

71. Ybarra M, Dos Santos TJ, Pinheiro CTC, et al. Rectal levothyroxine for the treatment of hypothyroidism: A case study. Pediatrics. 2018;142(2):e20173317. doi: https://doi.org/10.1542/peds.2017-3317

72. Kashiwagura Y, Uchida S, Tanaka S, et al. Clinical efficacy and pharmacokinetics of levothyroxine suppository in patients with hypothyroidism. Biol Pharm Bull. 2014;37(4):666-670. doi: https://doi.org/10.1248/bpb.b13-00998

73. Obeidat KA, Saadeh NA, As’ad A, Bakkar S. Successful management of hypothyroidism in gastric outlet obstruction using levothyroxine rectal enemas: A case report. Am J Case Rep. 2018;19(1):903-905. doi: https://doi.org/10.12659/AJCR.909437

74. Grijota-Martínez C, Bárez-López S, Ausó E, et al. Intranasal delivery of thyroid hormones in MCT8 deficiency. PLoS One. 2020;15(7):1-14. doi: https://doi.org/10.1371/journal.pone.0236113

75. Flores-Huerta S, Hernández-Montes H, Argote RM, Villalpando S. Effects of ethanol consumption during pregnancy and lactation on the outcome and postnatal growth of the offspring. Ann Nutr Metab. 1992;36(3):121-128. doi: https://doi.org/10.1159/000177706

76. Messina E, Ferraù F, Cannavò S. Oral mucositis induced by treatment with soft gel formulation of levothyroxine. Endocrine. 2018;59(1):226-227. doi: https://doi.org/10.1007/s12020-017-1312-7

77. Lehnert H, Castello-Bridoux C, Channaiah B, et al. Comparison of safety profiles of the new and old formulations of levothyroxine in a first global introduction in France. Exp Clin Endocrinol Diabetes. 2021;129(12):908-917. doi: https://doi.org/10.1055/a-1302-9343

78. Nagy EV, Perros P, Papini E, et al. New formulations of levothyroxine in the treatment of hypothyroidism: trick or treat? Thyroid. 2021;31(2):193-201. doi: https://doi.org/10.1089/thy.2020.0515